Strategy and rationale for urine collection protocols employed in the NEPTUNE study

Marie C Hogan, John C Lieske, Chrysta C. Lienczewski, Lisa L. Nesbitt, Larysa T. Wickman, Christina M. Heyer, Peter C Harris, Christopher J. Ward, Jamie L. Sundsbak, Luca Manganelli, Wenjun Ju, Jeffrey B. Kopp, Peter J. Nelson, Sharon G. Adler, Heather N. Reich, Lawrence B. Holzmann, Matthias Kretzler, Markus Bitzer

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Background: Glomerular diseases are potentially fatal, requiring aggressive interventions and close monitoring. Urine is a readily-accessible body fluid enriched in molecular signatures from the kidney and therefore particularly suited for routine clinical analysis as well as development of non-invasive biomarkers for glomerular diseases. Methods: The Nephrotic Syndrome Study Network (NEPTUNE; ClinicalTrials.gov Identifier NCT01209000) is a North American multicenter collaborative consortium established to develop a translational research infrastructure for nephrotic syndrome. This includes standardized urine collections across all participating centers for the purpose of discovering non-invasive biomarkers for patients with nephrotic syndrome due to minimal change disease, focal segmental glomerulosclerosis, and membranous nephropathy. Here we describe the organization and methods of urine procurement and banking procedures in NEPTUNE. Results: We discuss the rationale for urine collection and storage conditions, and demonstrate the performance of three experimental analytes (neutrophil gelatinase-associated lipocalin [NGAL], retinol binding globulin, and alpha-1 microglobulin) under these conditions with and without urine preservatives (thymol, toluene, and boric acid). We also demonstrate the quality of RNA and protein collected from the urine cellular pellet and exosomes. Conclusions: The urine collection protocol in NEPTUNE allows robust detection of a wide range of proteins and RNAs from urine supernatant and pellets collected longitudinally from each patient over 5 years. Combined with the detailed clinical and histopathologic data, this provides a unique resource for exploration and validation of new or accepted markers of glomerular diseases. Trial registration: ClinicalTrials.gov Identifier NCT01209000

Original languageEnglish (US)
JournalBMC Nephrology
DOIs
StateAccepted/In press - Nov 17 2015

Fingerprint

Urine Specimen Collection
Urine
Nephrotic Syndrome
Biomarkers
RNA
Exosomes
Thymol
Lipoid Nephrosis
Focal Segmental Glomerulosclerosis
Membranous Glomerulonephritis
Translational Medical Research
Globulins
Toluene
Body Fluids
Vitamin A
Proteins
Kidney

Keywords

  • Exosome
  • Urinalysis
  • Urine specimen collection

ASJC Scopus subject areas

  • Nephrology

Cite this

Strategy and rationale for urine collection protocols employed in the NEPTUNE study. / Hogan, Marie C; Lieske, John C; Lienczewski, Chrysta C.; Nesbitt, Lisa L.; Wickman, Larysa T.; Heyer, Christina M.; Harris, Peter C; Ward, Christopher J.; Sundsbak, Jamie L.; Manganelli, Luca; Ju, Wenjun; Kopp, Jeffrey B.; Nelson, Peter J.; Adler, Sharon G.; Reich, Heather N.; Holzmann, Lawrence B.; Kretzler, Matthias; Bitzer, Markus.

In: BMC Nephrology, 17.11.2015.

Research output: Contribution to journalArticle

Hogan, MC, Lieske, JC, Lienczewski, CC, Nesbitt, LL, Wickman, LT, Heyer, CM, Harris, PC, Ward, CJ, Sundsbak, JL, Manganelli, L, Ju, W, Kopp, JB, Nelson, PJ, Adler, SG, Reich, HN, Holzmann, LB, Kretzler, M & Bitzer, M 2015, 'Strategy and rationale for urine collection protocols employed in the NEPTUNE study', BMC Nephrology. https://doi.org/10.1186/s12882-015-0185-3
Hogan, Marie C ; Lieske, John C ; Lienczewski, Chrysta C. ; Nesbitt, Lisa L. ; Wickman, Larysa T. ; Heyer, Christina M. ; Harris, Peter C ; Ward, Christopher J. ; Sundsbak, Jamie L. ; Manganelli, Luca ; Ju, Wenjun ; Kopp, Jeffrey B. ; Nelson, Peter J. ; Adler, Sharon G. ; Reich, Heather N. ; Holzmann, Lawrence B. ; Kretzler, Matthias ; Bitzer, Markus. / Strategy and rationale for urine collection protocols employed in the NEPTUNE study. In: BMC Nephrology. 2015.
@article{c97ba78f541b478db68bc146132e9ecb,
title = "Strategy and rationale for urine collection protocols employed in the NEPTUNE study",
abstract = "Background: Glomerular diseases are potentially fatal, requiring aggressive interventions and close monitoring. Urine is a readily-accessible body fluid enriched in molecular signatures from the kidney and therefore particularly suited for routine clinical analysis as well as development of non-invasive biomarkers for glomerular diseases. Methods: The Nephrotic Syndrome Study Network (NEPTUNE; ClinicalTrials.gov Identifier NCT01209000) is a North American multicenter collaborative consortium established to develop a translational research infrastructure for nephrotic syndrome. This includes standardized urine collections across all participating centers for the purpose of discovering non-invasive biomarkers for patients with nephrotic syndrome due to minimal change disease, focal segmental glomerulosclerosis, and membranous nephropathy. Here we describe the organization and methods of urine procurement and banking procedures in NEPTUNE. Results: We discuss the rationale for urine collection and storage conditions, and demonstrate the performance of three experimental analytes (neutrophil gelatinase-associated lipocalin [NGAL], retinol binding globulin, and alpha-1 microglobulin) under these conditions with and without urine preservatives (thymol, toluene, and boric acid). We also demonstrate the quality of RNA and protein collected from the urine cellular pellet and exosomes. Conclusions: The urine collection protocol in NEPTUNE allows robust detection of a wide range of proteins and RNAs from urine supernatant and pellets collected longitudinally from each patient over 5 years. Combined with the detailed clinical and histopathologic data, this provides a unique resource for exploration and validation of new or accepted markers of glomerular diseases. Trial registration: ClinicalTrials.gov Identifier NCT01209000",
keywords = "Exosome, Urinalysis, Urine specimen collection",
author = "Hogan, {Marie C} and Lieske, {John C} and Lienczewski, {Chrysta C.} and Nesbitt, {Lisa L.} and Wickman, {Larysa T.} and Heyer, {Christina M.} and Harris, {Peter C} and Ward, {Christopher J.} and Sundsbak, {Jamie L.} and Luca Manganelli and Wenjun Ju and Kopp, {Jeffrey B.} and Nelson, {Peter J.} and Adler, {Sharon G.} and Reich, {Heather N.} and Holzmann, {Lawrence B.} and Matthias Kretzler and Markus Bitzer",
year = "2015",
month = "11",
day = "17",
doi = "10.1186/s12882-015-0185-3",
language = "English (US)",
journal = "BMC Nephrology",
issn = "1471-2369",
publisher = "BioMed Central",

}

TY - JOUR

T1 - Strategy and rationale for urine collection protocols employed in the NEPTUNE study

AU - Hogan, Marie C

AU - Lieske, John C

AU - Lienczewski, Chrysta C.

AU - Nesbitt, Lisa L.

AU - Wickman, Larysa T.

AU - Heyer, Christina M.

AU - Harris, Peter C

AU - Ward, Christopher J.

AU - Sundsbak, Jamie L.

AU - Manganelli, Luca

AU - Ju, Wenjun

AU - Kopp, Jeffrey B.

AU - Nelson, Peter J.

AU - Adler, Sharon G.

AU - Reich, Heather N.

AU - Holzmann, Lawrence B.

AU - Kretzler, Matthias

AU - Bitzer, Markus

PY - 2015/11/17

Y1 - 2015/11/17

N2 - Background: Glomerular diseases are potentially fatal, requiring aggressive interventions and close monitoring. Urine is a readily-accessible body fluid enriched in molecular signatures from the kidney and therefore particularly suited for routine clinical analysis as well as development of non-invasive biomarkers for glomerular diseases. Methods: The Nephrotic Syndrome Study Network (NEPTUNE; ClinicalTrials.gov Identifier NCT01209000) is a North American multicenter collaborative consortium established to develop a translational research infrastructure for nephrotic syndrome. This includes standardized urine collections across all participating centers for the purpose of discovering non-invasive biomarkers for patients with nephrotic syndrome due to minimal change disease, focal segmental glomerulosclerosis, and membranous nephropathy. Here we describe the organization and methods of urine procurement and banking procedures in NEPTUNE. Results: We discuss the rationale for urine collection and storage conditions, and demonstrate the performance of three experimental analytes (neutrophil gelatinase-associated lipocalin [NGAL], retinol binding globulin, and alpha-1 microglobulin) under these conditions with and without urine preservatives (thymol, toluene, and boric acid). We also demonstrate the quality of RNA and protein collected from the urine cellular pellet and exosomes. Conclusions: The urine collection protocol in NEPTUNE allows robust detection of a wide range of proteins and RNAs from urine supernatant and pellets collected longitudinally from each patient over 5 years. Combined with the detailed clinical and histopathologic data, this provides a unique resource for exploration and validation of new or accepted markers of glomerular diseases. Trial registration: ClinicalTrials.gov Identifier NCT01209000

AB - Background: Glomerular diseases are potentially fatal, requiring aggressive interventions and close monitoring. Urine is a readily-accessible body fluid enriched in molecular signatures from the kidney and therefore particularly suited for routine clinical analysis as well as development of non-invasive biomarkers for glomerular diseases. Methods: The Nephrotic Syndrome Study Network (NEPTUNE; ClinicalTrials.gov Identifier NCT01209000) is a North American multicenter collaborative consortium established to develop a translational research infrastructure for nephrotic syndrome. This includes standardized urine collections across all participating centers for the purpose of discovering non-invasive biomarkers for patients with nephrotic syndrome due to minimal change disease, focal segmental glomerulosclerosis, and membranous nephropathy. Here we describe the organization and methods of urine procurement and banking procedures in NEPTUNE. Results: We discuss the rationale for urine collection and storage conditions, and demonstrate the performance of three experimental analytes (neutrophil gelatinase-associated lipocalin [NGAL], retinol binding globulin, and alpha-1 microglobulin) under these conditions with and without urine preservatives (thymol, toluene, and boric acid). We also demonstrate the quality of RNA and protein collected from the urine cellular pellet and exosomes. Conclusions: The urine collection protocol in NEPTUNE allows robust detection of a wide range of proteins and RNAs from urine supernatant and pellets collected longitudinally from each patient over 5 years. Combined with the detailed clinical and histopathologic data, this provides a unique resource for exploration and validation of new or accepted markers of glomerular diseases. Trial registration: ClinicalTrials.gov Identifier NCT01209000

KW - Exosome

KW - Urinalysis

KW - Urine specimen collection

UR - http://www.scopus.com/inward/record.url?scp=84946944563&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84946944563&partnerID=8YFLogxK

U2 - 10.1186/s12882-015-0185-3

DO - 10.1186/s12882-015-0185-3

M3 - Article

C2 - 26577187

AN - SCOPUS:84946944563

JO - BMC Nephrology

JF - BMC Nephrology

SN - 1471-2369

ER -